FDA Approves Added Safety Info for Brolucizumab (Beovu) Label FDA Approves Added Safety Info for Brolucizumab (Beovu) Label

The FDA approved the addition of safety information about the risk for retinal vasculitis and/or retinal vascular occlusion in patients receiving the drug.News Alerts
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Ophthalmology News Alert Source Type: news